Diabetes Mellitus, Type 2
Conditions
Keywords
insulin, basal, titration, digital health
Brief summary
The digital health tool is an application (app) available on iOS and Android enabled mobile phones. Health Care Providers (HCPs) configure algorithms which can be tailored to individual patient's needs and then prescribe the app to support optimal basal insulin titration and dosing. In this study, participants will be recruited from a medical practice in which an HCP has prescribed a once-daily basal insulin. Participants will be trained on the use of the app utilizing their own mobile phone. During training, a brief self-assessment survey will be administered. After 90 days of usage, a telephone survey will be conducted. The baseline A1C results and the end of study A1C results will be collected from the patients' routine clinical care records. Data from the retrospective control group will be collected from a chart review of the same practice.
Interventions
DEVICEBasal Insulin Titration Application
Healthcare Providers (HCP) and the principal investigator (PI) will use an HCP portal to initiate a basal insulin titration algorithm. HCPs can customize the titration algorithm for every participant. Once a participant is prescribed an algorithm, they can download a mobile app on their phone with their HCPs corresponding titration plan. The app will prompt participants to enter their fasting glucose daily. Based on their fasting glucose and their HCPs titration plan, the application will display the participants daily basal insulin dose.
Sponsors
Amalgam Rx, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The design of this protocol involves a prospective and retrospective cohort. The prospective cohort includes 30 participants. In the retrospective chart review, participants will be matched to the prospective group for age, gender, and baseline A1C. (For this study, the use of the word 'matched' means that the retrospective patient charts will be matched as close as possible from available patient data within the Bay West Endocrinology medical record database and may not always be an exact match to the prospective group for age, gender, and baseline A1c.) The chart review will thus be conducted after the last subject is enrolled in the prospective arm of the study.
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
\- Prospective cohort: The participants will be patients with type 2 diabetes mellitus who are not at goal on their current dose of prescribed basal insulin (e.g. Lantus, Toujeo, Levemir, Tresiba, or Basaglar). Participants shall be age 21 or older, prescribed basal insulin within the past 18 months, own a compatible mobile phone, able to receive/make calls and read messages on their phone. There is no predefined gender or ethnic group. Participants should be generally healthy and not expected to be hospitalized for surgery or other medical care during the study period. \- Retrospective cohort: This will be a chart review. Participants will be matched to the prospective cohort for age, gender and baseline A1C. Patients should have been prescribed one of the basal insulins above.
Exclusion criteria
\- Prospective cohort: Participants with stage 4 or 5 kidney disease, active malignancies, variable glucocorticoid doses during the study period, severe visual impairment, or dementia will be excluded. Also, participants prescribed rapid-acting or premixed insulins (any insulin not on the above list) will be excluded. \- Retrospective cohort: Same as above.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Basal Insulin Dose | 90 days | Change in basal insulin dose from entry into study to completion of study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fasting Glucose in Target | 90 days | Proportion of participants whose fasting blood glucose is in the ADA target range by the end of the 90 day study period. |
| Titration Adherence | 90 days | Proportion of participants who adhered to their basal insulin dose adjustments according to their algorithm. |
| Change in A1C | 90 days | Change in hemoglobin A1C measure at the completion of the study as compared to baseline. |
| Change in Fasting Glucose | 90 days | Change in the average fasting blood glucose in the final week of the study as compared to the first week of the study. |
| Participant Satisfaction | 90 days | Demonstration of satisfaction with the app at the completion of the study. |
| Office Contacts | 90 days | Reduction in number of HCP contacts (live office visits and phone calls) regarding insulin management during 90 day period. |
| Change in Diabetes Distress | 90 days | Change in measures of diabetes distress at the completion of the study as compared to baseline. |
Countries
United States
Outcome results
None listed